Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/18/23
Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)Seeking Alpha • 12/14/23
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive YearGlobeNewsWire • 12/11/23
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported OutcomesGlobeNewsWire • 12/11/23
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term OutcomesGlobeNewsWire • 12/10/23
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple MyelomaGlobeNewsWire • 12/07/23
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IOGlobeNewsWire • 12/07/23
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology PortfolioGlobeNewsWire • 11/30/23
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)Seeking Alpha • 11/28/23
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future SalesInvestors Business Daily • 11/27/23
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseGlobeNewsWire • 11/27/23